Oxford Medical Products has developed Sirona, a hydrogel platform technology that is currently in human clinical trials for weight loss.
Sirona is taken as a pill, rapidly expanding in the stomach where it creates a sustained feeling of satiety. The hydrogel remains in the stomach 24/7 for several days before breaking down and passing naturally.
Weight management
Sirona has 2 key target markets:
Overweight Individuals (BMI 25-30): the majority of whom are ineligible for GLP-1 therapies such as Wegovy and Mounjaro and do not need their extremity. Sirona is ideally positioned as an early intervention to prevent these individuals progressing into obesity.
Weight Maintenance After GLP-1 Therapy: Sirona is uniquely positioned to support individuals transitioning off GLP-1 treatments, helping to prevent or minimize weight regain, allowing them to maintain their new weight long term.
Sirona is designed to fulfil all the criteria needed to provide a scalable and effective solution to the obesity epidemic:
-
Sirona will be accessible to the out-of-pocket market.
-
Unlike surgery or balloons, Sirona administration does not require any medical assistance and can be taken as a pill at home.
-
Sirona acts to reduce available stomach volume in a method analogous to the weight-loss mechanism of surgery and balloons.
-
Sirona is expected to be indicated for all individuals living with excessive weight (BMI >25).
-
Provides additional behavioural and psychological support for individuals on their weight-loss journey.
